Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Predicting the response to sumatriptan: the Sumatriptan Naratriptan Aggregate Patient Database.

Hans Christoph-Diener1, Michel Ferrari, Hank Mansbach

  • 1Dept. of Neurology, University of Essen, Hufelandstr. 55, 45147 Essen, Germany. h.diener@uni-essen.de

Neurology
|August 12, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Target Populations for Novel Triglyceride-Lowering Therapies.

Journal of the American College of Cardiology·2025
Same author

Advocacy through storytelling: challenging eating disorders and eating disorders stigma.

Journal of eating disorders·2024
Same author

Author Correction: The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial.

Nature medicine·2024
Same author

Letter: Severe underweight and sarcopenia in decompensated cirrhosis are associated with high FGF21 levels-authors' reply.

Alimentary pharmacology & therapeutics·2024
Same author

Randomized Trial of Pegozafermin in NASH. Reply.

The New England journal of medicine·2023
Same author

Clinical trial: Effects of pegozafermin on the liver and on metabolic comorbidities in subjects with biopsy-confirmed nonalcoholic steatohepatitis.

Alimentary pharmacology & therapeutics·2023
Same journal

Phenotype, Severity, and Therapy of Patients With LRP4 Antibody-Associated Myasthenia Gravis in the German Myasthenia Gravis Registry.

Neurology·2026
Same journal

Association of Changes in Intrinsic Capacity With Cognitive Decline and Dementia: A Prospective Cohort Study.

Neurology·2026
Same journal

Role of the Upper Motor Neuron in the Generation of Fasciculations in Early Disease Stages of Amyotrophic Lateral Sclerosis.

Neurology·2026
Same journal

Factors Associated With Disability Improvement and Worsening Independent of Attacks in Patients With AQP4-IgG+ NMOSD and MOGAD: A Multicenter Cohort Study.

Neurology·2026
Same journal

Cost-Effectiveness of Intracranial Aneurysm Screening: A Systematic Review.

Neurology·2026
Same journal

Rare Eating Epilepsy: Co-Occurrence of Focal Cortical Dysplasia and Gray Matter Heterotopia.

Neurology·2026
See all related articles

Migraine sufferers respond best to sumatriptan when pain is moderate and they can remain active. Lower baseline pain severity predicts better sumatriptan response for migraine relief.

Area of Science:

  • Neurology
  • Pharmacology
  • Clinical Trials

Background:

  • Sumatriptan and other 5HT(1B/1D) agonists (triptans) are established migraine treatments.
  • Factors influencing optimal response to sumatriptan are not well understood.

Purpose of the Study:

  • To identify predictors of headache relief and pain-free response to sumatriptan.
  • To analyze data from the Sumatriptan Naratriptan Aggregate Patient (SNAP) database.

Main Methods:

  • Analysis of 128 clinical trials involving 28,407 migraine sufferers.
  • Assessment of 24 univariate predictors in 3,706 patients using recursive partitioning and logistic regression.
  • Evaluation of sumatriptan 100 mg tablets versus placebo in a double-blind study.

Related Experiment Videos

Main Results:

  • Moderate baseline pain was the strongest predictor of headache relief (p = 3.32 x 10(-35)).
  • Absence of disability requiring bedrest, and lack of vomiting, nausea, or photophobia/phonophobia also predicted better response.
  • Sumatriptan treatment was the strongest predictor of relief, with pain severity and disability level being significant covariates.

Conclusions:

  • Pretreatment pain severity is the most crucial factor for sumatriptan efficacy in migraine.
  • Lower baseline pain intensity correlates with improved response to sumatriptan treatment.